AK002

( DrugBank: - / KEGG DRUG: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
98	Eosinophilic gastrointestinal disease	7

98. Eosinophilic gastrointestinal disease

Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135

trials per page:

Showing 1 to 7 of 7 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04856891 (ClinicalTrials.gov)	May 20, 2021	20/4/2021	A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy ...	Eosinophilic Duodenitis;Eosinophilic Gastroenteritis	Drug: AK002;Other: Placebo	Allakos, Inc.	NULL	Active, not recruiting	18 Years	80 Years	All	94	Phase 3	United States
2	NCT04620811 (ClinicalTrials.gov)	December 3, 2020	3/11/2020	An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerl ...	A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002in P ...	Eosinophilic Gastritis;Eosinophilic Duodenitis	Drug: lirentelimab	Allakos, Inc.	NULL	Enrolling by invitation	18 Years	80 Years	All	170	Phase 3	United States
3	EUCTR2019-004391-19-NL (EUCTR)	30/07/2020	13/05/2020	Study to Evaluate the Efficacy and Safety of AK002 in Subjects with Active Eosinophilic Esophagitis	A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficac ...	Active Eosinophilic Esophagitis (EoE) MedDRA version: 20.1;Level: PT;Classification code 10064212;Te ...	Product Code: AK002 INN or Proposed INN: not available	Allakos Inc.	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 2;Phase 3	United States;Australia;Netherlands
4	NCT04322708 (ClinicalTrials.gov)	July 6, 2020	24/3/2020	A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis	A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficac ...	Eosinophilic Esophagitis	Other: Placebo;Drug: lirentelimab (AK002)	Allakos, Inc.	NULL	Active, not recruiting	12 Years	80 Years	All	277	Phase 2/Phase 3	United States;Australia;Netherlands
5	NCT04322604 (ClinicalTrials.gov)	June 18, 2020	24/3/2020	A Study to Assess AK002in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred t ...	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and ...	Eosinophilic Gastritis;Eosinophilic Duodenitis	Drug: lirentelimab (AK002);Other: Placebo	Allakos, Inc.	NULL	Active, not recruiting	18 Years	80 Years	All	180	Phase 3	United States
6	NCT03664960 (ClinicalTrials.gov)	November 14, 2018	6/9/2018	An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis	A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 ...	Eosinophilic Gastritis;Eosinophilic Gastroenteritis;Eosinophilic Duodenitis	Drug: AK002	Allakos, Inc.	NULL	Active, not recruiting	18 Years	80 Years	All	58	Phase 2	United States
7	NCT03496571 (ClinicalTrials.gov)	July 18, 2018	6/4/2018	A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, ...	Eosinophilic Gastritis;Eosinophilic Gastroenteritis	Drug: AK002;Other: Placebo	Allakos, Inc.	NULL	Completed	18 Years	80 Years	All	65	Phase 2	United States

First Previous1Next Last